NCT05451914

Brief Summary

The purpose of this study is to conduct a two-arm, parallel-design, pragmatic randomized controlled trial of a patient portal intervention for diabetes, My Diabetes Care (MDC), to evaluate its effect on clinical outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
458

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Jul 2023

Typical duration for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 1, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 11, 2022

Completed
12 months until next milestone

Study Start

First participant enrolled

July 6, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 14, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 14, 2025

Completed
Last Updated

November 13, 2025

Status Verified

November 1, 2025

Enrollment Period

2 years

First QC Date

July 1, 2022

Last Update Submit

November 11, 2025

Conditions

Keywords

DiabetesPatient Web PortalsHealth Information Technology

Outcome Measures

Primary Outcomes (1)

  • Change in Blood Glucose Control

    Hemoglobin A1c will assessed using mail-in home HbA1c test kits and participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

Secondary Outcomes (10)

  • Change in Body Mass Index (BMI)

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  • Change in Low Density Lipoprotein (LDL)

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  • Urine Albumin-to-Creatinine Ratio

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  • Change in Blood Pressure Control

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  • Change in Diabetes Self-Care (General Diet Adherence)

    Baseline (T0), Three-month Follow-up (T1), Six-month Follow-Up (T2), Twelve-month Follow-up (T3)

  • +5 more secondary outcomes

Study Arms (2)

My Diabetes Care

EXPERIMENTAL

Patients have access to an existing patient web portal (i.e., Epic's MyChart) embedded with My Diabetes Care.

Other: My Diabetes Care

Usual Care

NO INTERVENTION

Patients will have access to an existing patient web portal (i.e., Epic's MyChart) NOT embedded with My Diabetes Care (i.e., usual care)

Interventions

My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.

Also known as: Patient-facing Diabetes Dashboard
My Diabetes Care

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 Diabetes Mellitus
  • Age 18-75 years old
  • Currently taking at least one medication for diabetes
  • Be a patient at Vanderbilt University Medical Center (VUMC) or Brigham and Women's Hospital (BWH)
  • Able to speak and read in English or Spanish
  • Have reliable access to a smartphone, tablet, or computer with internet access
  • Active patient web portal account (My Health at Vanderbilt at VUMC or Patient Gateway at BWH)

You may not qualify if:

  • Receiving dialysis,
  • Pregnant or planning to become pregnant within the next year,
  • Living in a long-term care facility.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • William Martinez, MD, MS

    Vanderbilt University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Medicine

Study Record Dates

First Submitted

July 1, 2022

First Posted

July 11, 2022

Study Start

July 6, 2023

Primary Completion

July 14, 2025

Study Completion

July 14, 2025

Last Updated

November 13, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will share

After study results are posted on clinical trials and published in a peer-reviewed journal, de-identified individual participant data that underlie the results reported will be available upon requests made to the principal investigator and ending after 36 months after publication.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Deidentified individual participant data that underlie the results reported will be available after publication in a peer-reviewed journal and posted on clinical trials and ending after 36 months of publication.
Access Criteria
Researchers should provide a methodologically sound proposal to achieve their proposed aims. Proposals may be submitted to the principal investigator up to 36 months following publication. To gain access, data requestors will need to sign a data access agreement.

Locations